Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer

NCT05455619 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

HR+/HER2-negative Breast Cancer
Metastatic Breast Cancer

Interventions

DRUG: Evexomostat

Sponsor

SynDevRx, Inc.